A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.
Daniel Yick Chin Heng(University of Calgary), Lori Wood(Dalhousie University), Min‐Han Tan(National Cancer Centre Singapore), Toni K. Choueiri(Harvard University), Lauren C. Harshman(Dana-Farber Cancer Institute), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Scott North, Sun Young Rha(Yonsei University), Jennifer J. Knox(National Cancer Center), Ulka N. Vaishampayan(University of Michigan), Christian Kollmannsberger(BC Cancer Agency), Mary J. MacKenzie(Cancer Care Ontario), Neeraj Agarwal(University of Utah), Jae‐Lyun Lee(Ulsan College), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 6
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k